van der Palen J, et al. - In this multicenter, randomized, open-label, placebo-device, crossover study, researchers assessed the potential benefits of using a single Ellipta dry powder inhaler (DPI) compared with two combinations of DPIs commonly used to deliver triple maintenance therapy by analyzing data of patients receiving inhaled COPD medication. The present data indicated that fewer patients with COPD made critical errors with the single DPI. Findings revealed that patients needed less instruction time, compared with each dual DPI combination. It was noted that significantly more patients preferred Ellipta over Diskus + HandiHaler or Turbuhaler + HandiHaler overall for taking their COPD medication and per the number of steps for taking their COPD medication.